Epilepsy market -snapshot- , weekly report Oct 17-25. News and market analysis of pharmaceutical companies. Competitive Intelligence.

1. EPILEPSY WEEKLY REPORT 102516

2. EPILEPSY WEEKLY REPORT 102516
NEWS - 101716-102516
APPROVALS
GW PHARMA
MARINUS PHARMA
PFIZER
ZYNERBA
UCB
MARKET REPORTS
EPILEPSY

3. 2016-10-25 13:14 pharmatimes.com
Martindale's oral epilepsy drug bags EU nods
UK-based Martindale Pharma has announced regulatory clearance of an oral
formulation of its epilepsy therapy clobazam in Europe....
GW PHARMA 2016-10-21 01:09 nytimes.com
GW Pharma to Cancel London Listing - New York Times
Telegraph.co.uk GW Pharma to Cancel London Listing New York Times (Reuters)
- Britains GW Pharmaceuticals Plc, a developer of marijuana-based epilepsy
treatments, said it planned to cancel its listing in Londons junior market and would
retain listing of its American Depositary Receipts (ADRs) on Nasdaq to simplify ...
UPDATE 1- Drug developer GW Pharma to cancel London listing Business Insider
Intention to Trade Exclusively on NASDAQ London South East (registration) (blog)
all 25 news articles&nbs...
2016-10-20 18:09 businessinsider.com
UPDATE 1-Drug developer GW Pharma to cancel London
listing - Business Insider
Telegraph.co.uk UPDATE 1- Drug developer GW Pharma to cancel London listing
Business Insider Oct 19 (Reuters) - Britains GW Pharmaceuticals Plc , a developer
of marijuana-based epilepsy treatments, said it planned to cancel its listing in
Londons junior market and would retain listing of its American Depositary Receipts
(ADRs) on Nasdaq to ... GW Pharma to Cancel London Listing New York Times
Intention to Trade Exclusively on NASDAQ London South East (registration) (blog)
all 24 news articles ...
APPROVALS
2016-10-19 18:40 benchmarkmonitor.com
Mid Cap Losers: GW Pharmaceuticals plc
(NASDAQ:GWPH), Exelixis, Inc. (NASDAQ:EXEL),
Chemtura Corporation ... - Benchmark Monitor
Mid Cap Losers: GW Pharmaceuticals plc (NASDAQ:GWPH), Exelixis, Inc.
(NASDAQ:EXEL), Chemtura Corporation ... Benchmark Monitor GW
Pharmaceuticals plc (NASDAQ:GWPH) cannabinoid drug Epidiolex has achieved
primary endpoint in treating Lennox-Gastaut syndrome – a severe form of
childhood epilepsy – speeding through phase three trials...
2016-10-19 10:08 dailymail.co.uk
Drug developer GW Pharma to cancel London listing -
Daily Mail
DIGITALLOOK Drug developer GW Pharma to cancel London listing Daily Mail Oct
19 (Reuters) - Britains GW Pharmaceuticals Plc , a developer of marijuana-based
epilepsy treatments, said it planned to cancel its listing in Londons junior market
and would retain listing of its American Depositary Receipts (ADRs) on Nasdaq
to ... GW Pharmaceuticals to cancel London listing London South East
(registration)(blog) all 12 news articles »...

4. MARINUS 2016-10-24 19:10 google.com
Marinus to proceed to Phase 2 with ganaxolone in life-
threatening form of epilepsy
Results from a 36-subject Phase 1 dose-escalation study to assess the safety,
pharmacokinetics and pharmacodynamics of Marinus Pharmaceuticals ......
2016-10-21 21:09 mmahotstuff.com
Rating Sentiment Summary: This is what analysts have
to say about Marinus Pharmaceuticals Inc
(NASDAQ:MRNS ... - MoneyMakingArticles
MoneyMakingArticles Rating Sentiment Summary: This is what analysts have to
say about Marinus Pharmaceuticals Inc (NASDAQ:MRNS ... MoneyMakingArticles
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company . The
company has a market cap of $23.72 million...
PFIZER 2016-10-24 05:08 reliawire.com
Lyrica: The Epilepsy Drug That Treats Chronic Nerve
Pain - ReliaWire
ReliaWire Lyrica: The Epilepsy Drug That Treats Chronic Nerve Pain ReliaWire
Lyrica is the brand name for a prescription medicine called pregabalin. Although it
is an anticonvulsant, or an anti- epileptic drug , pregabalin is commonly prescribed
to alleviate nerve or neuropathic pain – a type of pain caused by damage to, or a ...
Taking pregabalin drug during pregnancy could lead to major birth defects News-
Medical...
ZYNERBA 2016-10-25 16:09 dailyquint.com
Zynerba Pharmaceuticals Inc. (ZYNE) Stock Rating
Upgrade by The Zacks Investment Research - DailyQuint
Zynerba Pharmaceuticals Inc. (ZYNE) Stock Rating Upgrade by The Zacks
Investment Research DailyQuint According to Zacks, "Zynerba Pharmaceuticals,
Inc. is a specialty pharmaceutical company which focuses on developing and
commercializing proprietary synthetic cannabinoid therapeutics formulated for
transdermal delivery...

5. 2016-10-21 06:08 com-unik.info
Zynerba Pharmaceuticals Inc. (ZYNE) Upgraded at
Zacks ... - Community Financial News
Community Financial News Zynerba Pharmaceuticals Inc. (ZYNE) Upgraded at
Zacks ... Community Financial News Zynerba Pharmaceuticals Inc.
(NASDAQ:ZYNE) was upgraded by Zacks Investment Research from a "sell" rating
to a "hold" rating in a research note issued on ... Zynerba Pharmaceuticals Inc
(NASDAQ:ZYNE) has been upgraded to Hold in a statement by Zacks
Investment ... Breaking Finance News all 5 news articles »...
2016-10-20 17:09 com-unik.info
Zynerba Pharmaceuticals Inc. (ZYNE) Upgraded at Zacks
Investment Research - Community Financial News
Community Financial News Zynerba Pharmaceuticals Inc. (ZYNE) Upgraded at
Zacks Investment Research Community Financial News Why Alibaba = Google +
Facebook +Amazon. Alizila. Find out ... According to Zacks, "Zynerba
Pharmaceuticals, Inc...
2016-10-19 23:09 baseballnewssource.com
Equities Analysts Set Expectations for Zynerba
Pharmaceuticals Inc.'s FY2019 Earnings (ZYNE) - BBNS
Equities Analysts Set Expectations for Zynerba Pharmaceuticals Inc.s FY2019
Earnings (ZYNE) BBNS Zynerba Pharmaceuticals logo Zynerba Pharmaceuticals
Inc. (NASDAQ:ZYNE) – Research analysts at Roth Capital reduced their FY2019
earnings per share (EPS) estimates for Zynerba Pharmaceuticals in a report
released on Monday...
UCB 2016-10-25 04:16 medscape.com
EMA Recommends Safety Measures for Levetiracetam in
Epilepsy - Medscape
EMA Recommends Safety Measures for Levetiracetam in Epilepsy Medscape To
combat accidental overdose, the European Medicines Agency (EMA) is
recommending several safety measures when using the oral solution version of ...
and more »...

6. 2016-10-25 03:54 labiotech.eu
New Partnership comes to the Rescue in Neurological
Diseases - Labiotech.eu (blog)
New Partnership comes to the Rescue in Neurological Diseases Labiotech.eu
(blog) Developing effective treatments for neurological diseases is a big challenge
in medicine. But here come UCB and Evotec with a new partnership that could help
those suffering from epilepsy and Parkinsons...
MARKET REPORTS 2016-10-25 03:54 medgadget.com
Epileptic Anticonvulsants Market Trends and industry
Analysis – 2020 - Medgadget (blog)
Epileptic Anticonvulsants Market Trends and industry Analysis – 2020 Medgadget
(blog) A detailed profile of the top key players is presented in the report. Some of
the key corporations in the epileptic anticonvulsants market include Novartis AG,
Johnson & Johnson (J&J), UCB Group, Abbot Laboratories, Pfizer Inc...
EPILEPSY 2016-10-25 04:10 news-medical.net
New study reveals conversion of oral cannabidiol to THC
by acidic fluids in the stomach - News-Medical.net
News-Medical.net New study reveals conversion of oral cannabidiol to THC by
acidic fluids in the stomach News-Medical.net A new study demonstrating the
conversion of oral cannabidiol (CBD) to the psychoactive component
tetrahydrocannabinol (THC) in the presence of gastric fluids could explain why
children given CBD to treat epilepsy had an unexpectedly high rate of ......
2016-10-25 04:10 news-medical.net
New technique can help detect brain regions that trigger
seizures in people with epilepsy - News-Medical.net
News-Medical.net New technique can help detect brain regions that trigger
seizures in people with epilepsy News-Medical.net Scientists at the University of
Exeter have developed a pioneering new technique that could revolutionise the
surgical treatment of epilepsy . The team of scientists, led by Dr Marc Goodfellow
and Professor John Terry, have developed the ground-breaking ... and more »...
2016-10-24 06:09 upi.com
Newer epilepsy drugs may be safer during pregnancy -
UPI.com
UPI.com Newer epilepsy drugs may be safer during pregnancy UPI.com But the
commonly prescribed anti- seizure drug valproate was linked with lower IQs in
children, especially when taken at higher doses, researchers say...

7. 2016-10-23 21:08 ganjapreneur.com
Australian Hospital Begins CBD Epilepsy Drug Trial for
Children - Ganjapreneur
Ganjapreneur Australian Hospital Begins CBD Epilepsy Drug Trial for Children
Ganjapreneur The Childrens Hospital Network in Australia is conducting a clinical
trial of Epidiolex, a CBD-rich, cannabis-derived drug , to determine its effectiveness
for children suffering from epilepsy , according to a report by the Maitland
Mercury...
2016-10-22 09:09 upi.com
Study: Risk for autism increased by relative with
epilepsy - UPI.com
UPI.com Study: Risk for autism increased by relative with epilepsy UPI.com
LINKöPING, Sweden, June 17 (UPI) -- Having a diagnosis of epilepsy in childhood
increases risk for autism spectrum disorder, though just having a family member
with the condition may also significantly raise the risk...
2016-10-22 07:09 upi.com
Changes in heart activity linked to epilepsy - UPI.com
UPI.com Changes in heart activity linked to epilepsy UPI.com CLEVELAND, March
9 (UPI) -- Researchers found they can detect epilepsy based on changes to heart
activity, even in the absence of seizures , according to a new study...
2016-10-22 07:09 upi.com
2016-10-23 21:08 medicalxpress.com
Epilepsy drug could help treat Alzheimer's disease -
Medical Xpress
Medical Xpress Epilepsy drug could help treat Alzheimers disease Medical Xpress
In this newest research, Dr. Haakon Nygaard, the Fipke Professor in Alzheimers
Research in UBCs Faculty of Medicine, tested the effects of brivaracetam, an
anticonvulsant drug still in clinical development for epilepsy , and closely related
to ... and more »...
2016-10-23 11:09 upi.com
Epilepsy may triple ADHD risk, Danish study finds -
UPI.com
UPI.com Epilepsy may triple ADHD risk, Danish study finds UPI.com The
investigators found those with epilepsy seemed to have nearly three times the risk
of developing ADHD compared to children without epilepsy . And children who had
fever-related seizures appeared to have an almost 30 percent increased risk of
ADHD...

8. 2016-10-21 19:10 upi.com
Epilepsy drugs may induce some psychotic disorders,
study says - UPI.com
UPI.com Epilepsy drugs may induce some psychotic disorders, study says
UPI.com 9 (UPI) -- Epilepsy patients are already at increased risk for psychiatric
conditions and psychosis, though drugs used to treat the condition have been
suspected of increasing risk for psychotic episodes, and a new study shows this
may be true ... and more »...
2016-10-19 18:40 healthaim.com
Cannabis Oil: The Truth Behind This Cancer Cure -
Health Aim
Health Aim Cannabis Oil: The Truth Behind This Cancer Cure Health Aim Amyleas
parents have been seeking for a cure for her seizures caused by a rare form of
epilepsy . In a spark of luck, the doctors at the Childrens Hospital in Aurora,
Colorado allowed the administration of Charlottes Web, a type of cannabis oil, on
......
2016-10-19 18:40 scopeblog.stanford.edu
Newfound brain pathway may let epilepsy patients steer
around medical marijuana's nasty side effects - Scope
(blog)
Scope (blog) Newfound brain pathway may let epilepsy patients steer around
medical marijuanas nasty side effects Scope (blog) While its association with
mental illness (for example, schizophrenia) is still debated, its component active
substances are known to saturate endocannabinoid receptors in an all-important
part of the brain called the hippocampus, obliterating both ......

11. Federal Cannabis Production License Issued to the Green Organic Dutchman Ltd
Issued By: Green Organic Dutchman Ltd Publication Date: 31-Dec-2016
...eco-friendly, carbon sensitive design. With a 10 kw solar array and geothermal heating in addition to our reforestation efforts, we value
ecological practices on our 25-acre farm.”Jeannette's daughter Breanne passed away in 2003 as a result of a severe epilepsy disorder,
very likely Dravet syndrome. Breanne was never given cannabis as reports of cannabis for seizure treatment weren't widely available at the
time. “My hope is that cannabis medicines will help to reduce the devastating impact of sei
...
Clobazam Oral Suspension Approved in Seven European Countries
Issued By: Martindale Pharma Publication Date: 24-Oct-2016
...world's first oral liquid suspension version of clobazam to receive regulatory approval, which has been available from Martindale Pharma
under the tradename Tapclob since May 2013. Clobazam oral suspension is used principally as an adjunctive therapy for epilepsy with the
formulation particularly suitable for children and young adults. Epaclob/Silocalm are approved in two strengths, 5mg/5ml and 10mg/5ml,
and will be supplied in packs containing dosing syringes and dosage cups to facilitate accurat
...
US FDA Considers Newron's Re-Submitted NDA for Xadago to be a Complete, Class 2 Response to Complete Response
Letter
Issued By: Newron Pharmaceuticals SpA; Zambon Co SpA; US WorldMeds LLC Publication Date: 21-Oct-2016
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the
development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, and its partners Zambon S.p.A.
and US WorldMeds, LLC, announced today that the US Food and Drug Administration (FDA) considers the September 2016 re-submission
of the US NDA by Newron to be a complete, Class 2 response to FDA's March 28, 2016 Complete Response Letter (CRL), and has dete
...
Pacira Pharmaceuticals Continues to Build Out Robust Commercial Leadership Team Company Appoints Thomas Sluby
as Vice President, Sales and Matthew Lehmann as Vice President, Marketing
Issued By: Pacira Pharmaceuticals Inc Publication Date: 20-Oct-2016
...Sluby also held several management roles during a 15-year period at Eisai, Inc., including National Sales Director of Neurology,
Gastroenterology and LTC/Hospital, where he drove revenue in therapeutic areas ranging from Alzheimer's and acid reflux to epilepsy and
low-molecular-weight heparin.Prior to Pacira, Mr. Lehmann held various executive positions during a 21-year career at AstraZeneca, most
recently as Head of the Neuroscience Franchise where he was responsible for the successful market bui
...
Sage Therapeutics and Collaborators Publish New Pre-clinical Data in Neuropharmacology Demonstrating a Novel Metabotropic Mechanism
of Sage Compounds Resulting in Enhanced Effects
Issued By: SAGE Therapeutics Inc Publication Date: 20-Oct-2016
...findings are profoundly relevant for Sage and our portfolio of novel GABA compounds, particularly as reduced expression of extrasynaptic
GABAA receptors has been demonstrated in human and rodent models of status epilepticus, postpartum depression and forms of
epilepsy,” said Jim Doherty, PhD, Senior Vice President of Research at Sage. “We believe the potential ability of neuroactive steroids, and
Sage's compounds in particular, to restore tonic inhibition by increasing the surface expression and t
...
PRESS RELEASE, THOMSON REUTERS CORTELLIS

12. PixarBio Corporation, Expands PPM to $40,000,000, Extends PPM One Week to Close October 28, 2016 and
Promotes Ken Stromsland to Vice President, CIO & External Communications
Issued By: PixarBio Corp Publication Date: 20-Oct-2016
...pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery
systems for post-operative pain. PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain,
epilepsy, Parkinson's disease, and spinal cord injury. Our lead product platform, NeuroRelease, has achieved sustained therapeutic
release of non-opiate drugs for post-operative, acute and chronic pain in pre-clinical models. For more infor
...
Evotec and UCB Sign Multi-Year CNS Pharmacology Agreement
Issued By: Evotec AG Publication Date: 20-Oct-2016
...UCB has over 7,700 employees worldwide with research and early development scientists based in Belgium (Central Nervous System)
and UK (immunology) supporting an innovative pipeline of novel therapeutics. UCB's core products are treating patients with epilepsy,
rheumatoid arthritis and Parkinson's disease. UCB recognises that the identification of new and innovative protein targets remains a
core challenge for the pharmaceutical industry. UCB therefore continues to invest internally, externally an
...
XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with
Congenital Hyperinsulinism
Issued By: XOMA Corp Publication Date: 19-Oct-2016
...is the major physiologic hormone for controlling blood glucose levels. Abnormal increases in insulin secretion can lead to profound
hypoglycemia (low blood sugar), a state that can result in significant morbidities, including brain damage, seizures and epilepsy. XOMA,
leveraging its scientific expertise in allosteric monoclonal antibodies, developed the XMet platform, consisting of separate classes of
selective insulin receptor modulators (SIRMs) that could have a major effect on treating patients
...
Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus
Issued By: Marinus Pharmaceuticals Inc Publication Date: 19-Oct-2016
...Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat
epilepsy and neuropsychiatric disorders, today announced that in its Phase 1 dose-escalation study, ganaxolone intravenous (IV)
achieved...mechanism of action, demonstrated efficacy and safety and convenient dosing, to improve the lives of patients suffering from
epilepsy and neuropsychiatric disorders. Ganaxolone is a CNS-selective GABAA modulator that acts on a
...
Vitality Biopharma Reports on Initial Cannabinoid Drug Formulation Studies
Issued By: Vitality Biopharma Inc Publication Date: 19-Oct-2016
...where an individual's immune system attacks their intestines, rectum, and other parts of their digestive tract. This disease afflicts 1.4
million Americans and often affects children, with most patients receiving their diagnosis prior to age 30. As with epilepsy, dramatic
clinical trial results have been documented through the use of cannabinoids, including an ability to induce remission of Crohn's disease.
Large state-funded and independently-managed clinical trials are now underway to further do
...

13. GW Pharmaceuticals plc Announces Intention to Continue Trading Exclusively on NASDAQ and Planned
Cancellation of Trading of Ordinary Shares on AIM
Issued By: GW Pharmaceuticals plc Publication Date: 19-Oct-2016
...its investigational product for the treatment of a number of rare childhood-onset epilepsy disorders, as well as advance its
cannabinoid product pipeline.BackgroundHaving...outside the United States. GW is advancing an orphan drug program in the field
of epilepsy with a focus on Epidiolex (cannabidiol), which is in Phase 3 clinical development...candidates which includes
compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit ww
...
Pediatric Research Consortia announce CAVATICA Platform for Analyzing Research Data on Pediatric Cancers
and Rare Diseases
Issued By: Childrens Hospital of Philadelphia Publication Date: 17-Oct-2016
...CAVATICA, which also launches out of beta today, will enable researchers to collaboratively access, share and rapidly analyze
data collected about diseases impacting children, including pediatric cancers, congenital disorders and rare diseases such as
epilepsy and autism.By making large volumes of genomic and other types of data from multiple diseases available, within a system
researchers can use to share and analyze it, CAVATICA is answering the Cancer Moonshot's call to de-silo data and make it
...
Zynerba Provides Clinical Update for Lead Development Candidates – ZYN001 and ZYN002
Issued By: Zynerba Pharmaceuticals Inc Publication Date: 17-Oct-2016
...in the first half of 2017. Two Phase 2 clinical trials are ongoing for ZYN002, in adults with refractory epilepsy and in knee pain
associated with osteoarthritis. Phase 2 clinical trials in patients with Fragile X Syndrome...2016, the company initiated the Phase 2
STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial of ZYN002 CBD gel in refractory epilepsy
patients with focal seizures. In August 2016, the Phase 2 STOPI(Synthetic Transdermal Cannabid
...
Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia
Issued By: Addex Therapeutics Ltd Publication Date: 17-Oct-2016
...dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical
program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen
Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start phase I
and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use
disorder and nico
...

14. Report 2016-10-25 Published By: Andrea Malizia